These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 27112707)

  • 1. Designer Thiopurine-analogues for Optimised Immunosuppression in Inflammatory Bowel Diseases.
    Atreya I; Diall A; Dvorsky R; Atreya R; Henninger C; Grün M; Hofmann U; Schaeffeler E; López-Posadas R; Daehn I; Zenker S; Döbrönti M; Neufert C; Billmeier U; Zundler S; Fritz G; Schwab M; Neurath MF
    J Crohns Colitis; 2016 Oct; 10(10):1132-43. PubMed ID: 27112707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rac1/pSTAT3 expression: A pharmacodynamic marker panel as a first step toward optimization of thiopurine therapy in inflammatory bowel disease patients.
    Deben DS; van Adrichem AJ; Drent R; Puts S; Pelzer KEJM; van Bodegraven AA; Wong DR; Leers MPG
    Cytometry A; 2022 Feb; 101(2):167-176. PubMed ID: 34595833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rac1 as a Potential Pharmacodynamic Biomarker for Thiopurine Therapy in Inflammatory Bowel Disease.
    Seinen ML; van Nieuw Amerongen GP; de Boer NK; Mulder CJ; van Bezu J; van Bodegraven AA
    Ther Drug Monit; 2016 Oct; 38(5):621-7. PubMed ID: 27465973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A report on the potential of Rac1/pSTAT3 protein levels in T lymphocytes to assess the pharmacodynamic effect of thiopurine therapy in Inflammatory Bowel Disease patients.
    Deben DS; Creemers RH; van Adrichem AJ; Drent R; Merry AHH; Leers MPG; van Bodegraven AA; Wong DR
    Sci Rep; 2022 Sep; 12(1):15806. PubMed ID: 36138194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rac1 Polymorphisms and Thiopurine Efficacy in Children With Inflammatory Bowel Disease.
    Lev-Tzion R; Renbaum P; Beeri R; Ledder O; Mevorach R; Karban A; Koifman E; Efrati E; Muise AM; Chowers Y; Turner D
    J Pediatr Gastroenterol Nutr; 2015 Oct; 61(4):404-7. PubMed ID: 25885881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of GTPase Rac1 in endothelium by 6-mercaptopurine results in immunosuppression in nonimmune cells: new target for an old drug.
    Marinković G; Kroon J; Hoogenboezem M; Hoeben KA; Ruiter MS; Kurakula K; Otermin Rubio I; Vos M; de Vries CJ; van Buul JD; de Waard V
    J Immunol; 2014 May; 192(9):4370-8. PubMed ID: 24670805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thiopurine use associated with reduced B and natural killer cells in inflammatory bowel disease.
    Lord JD; Shows DM
    World J Gastroenterol; 2017 May; 23(18):3240-3251. PubMed ID: 28566883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Azathioprine suppresses ezrin-radixin-moesin-dependent T cell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins.
    Poppe D; Tiede I; Fritz G; Becker C; Bartsch B; Wirtz S; Strand D; Tanaka S; Galle PR; Bustelo XR; Neurath MF
    J Immunol; 2006 Jan; 176(1):640-51. PubMed ID: 16365460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rac Attack: Modulation of the Small GTPase Rac in Inflammatory Bowel Disease and Thiopurine Therapy.
    Seinen ML; van Nieuw Amerongen GP; de Boer NK; van Bodegraven AA
    Mol Diagn Ther; 2016 Dec; 20(6):551-557. PubMed ID: 27604084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does lymphopenia or macrocytosis reflect 6-thioguanine levels in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine?
    Heerasing NM; Ng JF; Dowling D
    Intern Med J; 2016 Apr; 46(4):465-9. PubMed ID: 26425841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes.
    Tiede I; Fritz G; Strand S; Poppe D; Dvorsky R; Strand D; Lehr HA; Wirtz S; Becker C; Atreya R; Mudter J; Hildner K; Bartsch B; Holtmann M; Blumberg R; Walczak H; Iven H; Galle PR; Ahmadian MR; Neurath MF
    J Clin Invest; 2003 Apr; 111(8):1133-45. PubMed ID: 12697733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IMPDH activity in thiopurine-treated patients with inflammatory bowel disease - relation to TPMT activity and metabolite concentrations.
    Haglund S; Taipalensuu J; Peterson C; Almer S
    Br J Clin Pharmacol; 2008 Jan; 65(1):69-77. PubMed ID: 17662091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatotoxicity associated with 6-methyl mercaptopurine formation during azathioprine and 6-mercaptopurine therapy does not occur on the short-term during 6-thioguanine therapy in IBD treatment.
    van Asseldonk DP; Seinen ML; de Boer NK; van Bodegraven AA; Mulder CJ
    J Crohns Colitis; 2012 Feb; 6(1):95-101. PubMed ID: 22261533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease.
    Gearry RB; Barclay ML
    J Gastroenterol Hepatol; 2005 Aug; 20(8):1149-57. PubMed ID: 16048561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reactivity against microsatellite instability-induced frameshift mutations in patients with inflammatory bowel disease.
    Kuehn F; Klar E; Bliemeister A; Linnebacher M
    World J Gastroenterol; 2015 Jan; 21(1):221-8. PubMed ID: 25574094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine.
    Nielsen OH; Vainer B; Rask-Madsen J
    Aliment Pharmacol Ther; 2001 Nov; 15(11):1699-708. PubMed ID: 11683683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Should thiopurine methyltransferase genotypes and phenotypes be measured before thiopurine therapy in patients with inflammatory bowel disease?
    Fangbin Z; Xiang G; Minhu C; Liang D; Feng X; Min H; Pinjin H
    Ther Drug Monit; 2012 Dec; 34(6):695-701. PubMed ID: 23149442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic drug monitoring of thiopurine metabolites in adult thiopurine tolerant IBD patients on maintenance therapy.
    Gilissen LP; Wong DR; Engels LG; Bierau J; Bakker JA; Paulussen AD; Romberg-Camps MJ; Stronkhorst A; Bus P; Bos LP; Hooymans PM; Stockbrügger RW; Neef C; Masclee AA
    J Crohns Colitis; 2012 Jul; 6(6):698-707. PubMed ID: 22398098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early preservation of effector functions followed by eventual T cell memory depletion: a model for the delayed onset of the effect of thiopurines.
    Ben-Horin S; Goldstein I; Fudim E; Picard O; Yerushalmi Z; Barshack I; Bank I; Goldschmid Y; Meir SB; Mayer L; Chowers Y
    Gut; 2009 Mar; 58(3):396-403. PubMed ID: 18832521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NK cells are biologic and biochemical targets of 6-mercaptopurine in Crohn's disease patients.
    Yusung S; McGovern D; Lin L; Hommes D; Lagishetty V; Braun J
    Clin Immunol; 2017 Feb; 175():82-90. PubMed ID: 28011186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.